

# THE PRIMARY CARE COMPANION TO THE JOURNAL OF CLINICAL PSYCHIATRY

Subject Index to Volume 4: January 2002 Through December 2002

## ACADEMIC HIGHLIGHTS

Using atypical antipsychotics in primary care. 232–243

## Addiction

Successful pain management for the recovering addicted patient.  
Prater, 125–131

## S-Adenosylmethionine (SAME)

Case report of a manic episode triggered by S-adenosylmethionine (SAME)  
[letter]. Berigan, 159

## Adolescents

Possible link between attention-deficit/hyperactivity disorder and  
reproductive complications. Lyman, 104–108

## Alzheimer's Disease

Practical principles for the management of Alzheimer's disease.  
Christensen, 63–69

## Anticonvulsants

Uses of newer anticonvulsants: an update [letter]. Berigan, 200

## Antipsychotics see also specific drugs

Using atypical antipsychotics in primary care [ACADEMIC HIGHLIGHTS].  
232–243

## Association of Medicine and Psychiatry

Abstracts from the 2001 Annual Meeting of The Association. 162–163

## Asthma

Depressive symptoms in inner-city children with asthma. Morrison, 174–177

## Attention-Deficit/Hyperactivity Disorder

Novel Treatments for Attention-Deficit/Hyperactivity Disorder in Children  
and Adults [EDITOR'S CHOICE]. Suppl 4, 1–64

Possible link between attention-deficit/hyperactivity disorder and  
reproductive complications. Lyman, 104–108

## Bipolar Disorder

Comparison of risperidone and olanzapine in bipolar and schizoaffective  
disorders. Masand, 70–73

Mood disorder questionnaire: a simple, patient-rated screening instrument  
for bipolar disorder. Hirschfeld, 9–11

Olanzapine for the treatment of bipolar disorder [letter].

Ahmed; Masand reply, 113–114

## Books Reviewed

Clinton T, Ohlschlager G (eds): *Competent Christian Counseling, Vol. 1: Foundations and Practice of Compassionate Soul Care*. Parham, 160

Green MF: *Schizophrenia Revealed: From Neurons to Social Interactions*. Blackwelder, 80

Kennedy DM: *The ADHD-Autism Connection: A Step Toward More Accurate Diagnosis and Effective Treatments*. Globus, 115

Magee M, D'Antonio M: *The Best Medicine: Doctors, Patients, and the Covenant of Caring*. Roberts, 32

Martell CR, Addis ME, Jacobson NS: *Depression in Context: Strategies for Guided Action*. Buyck, 201

Rudd MD, Joiner T, Rajab MH: *Treating Suicidal Behavior: An Effective, Time-Limited Approach*. Zylstra, 251

## Bupropion

Bupropion-associated withdrawal symptoms revisited: a case report [letter].  
Berigan, 78

Many uses of bupropion and bupropion sustained release (SR) in adults  
[letter]. Berigan, 30–32

## Chest Pain

Panic disorder and chest pain: mechanisms, morbidity, and management.  
Huffman, 54–62

## Children

Court appointed volunteers for abused and neglected children. Justin, 17–19

Depressive symptoms in inner-city children with asthma. Morrison, 174–177

## Cognitive-Behavioral Therapy

Contributions of cognitive-behavioral approaches to the clinical management  
of insomnia. Morin, Suppl 1, 21–26

## Comorbidity

Comorbid psychiatric disorders and predictors of pain management program  
success in patients with chronic pain. Workman, 137–140

## Continuing Medical Education

Physician education [publisher's note]. 124

## Court Appointed Special Advocate

Court appointed volunteers for abused and neglected children. Justin, 17–19

## Depression

Depression with atypical features: diagnostic validity, prevalence,  
and treatment. Quitkin, 94–99

Depressive symptoms in inner-city children with asthma. Morrison, 174–177

Escitalopram: a new SSRI for the treatment of depression in primary care.

Culpepper, 209–214

Evaluating the impact of an educational program on practice patterns

of Canadian family physicians interested in depression treatment.

Kutcher, 224–231

Feasibility of using the Spanish PHQ-9 to screen for depression in primary  
care in Honduras. Wulsin, 191–195

## Dermatitis

Case report of drug-induced dermatitis with weekly fluoxetine [letter].  
Gupta, 78–79

## Diagnosis and Classification

Depression with atypical features: diagnostic validity, prevalence,  
and treatment. Quitkin, 94–99

## DIARY FROM THE FRONT LINES

Cocktails and kitchen sinks. Wolff, 244–245

Don't cry wolf with me. Wolff, 153–154

Feeling good and losing weight: the chicken or the egg? Wolff, 196–197

Hypervigilant? who, me? Wolff, 109–110

Post-call blues. Wolff, 25–26

Yes, we have no bananas. Wolff, 74–75

## Dyskinesia

Case report of methylphenidate-induced dyskinesia [letter].  
Heinrich, 158–159

## EDITOR'S CHOICE SUPPLEMENTS

Novel Treatments for Attention-Deficit/Hyperactivity Disorder in Children  
and Adults. Suppl 4, 1–64

Safety Profiles of Mood Stabilizers, Antipsychotics, and Broad-Spectrum  
Psychotropics. Suppl 2, 1–65

Treating Sexual Dysfunction: Psychiatry's Role in the Age of Sildenafil.  
Suppl 3, 1–25

## Education

Developing family relationship competencies [editorial]. Manning, 40

Evaluating the impact of an educational program on practice patterns of  
Canadian family physicians interested in depression treatment. Kutcher,  
224–231

Rebuilding family relationship competencies as a primary health intervention.  
Reiss-Brennan, 41–53

## Escitalopram

Escitalopram: a new SSRI for the treatment of depression in primary care.  
Culpepper, 209–214

Stereoisomers in psychiatry: the case of escitalopram. Burke, 20–24

## Family Health

Developing family relationship competencies [editorial]. Manning, 40

Rebuilding family relationship competencies as a primary health intervention.  
Reiss-Brennan, 41–53

**Fatigue**

Clinical dimensions of fatigue. Greenberg, 90–93  
 Modafinil treatment of excessive daytime sedation and fatigue associated with topiramate. Berigan, 249–50

**Fluoxetine**

Case report of drug-induced dermatitis with weekly fluoxetine [letter]. Gupta, 78–79

**Honduras**

Feasibility of using the Spanish PHQ-9 to screen for depression in primary care in Honduras. Wulsin, 191–195

**Hypnotics see also specific drugs**

Managing dependence and withdrawal with newer hypnotic medications in the treatment of insomnia. Lader, Suppl 1, 33–37  
 Pharmacotherapy of insomnia: efficacy and rebound with hypnotic drugs. Dikeos, Suppl 1, 27–32  
 Residual effects on memory and psychomotor performance of zaleplon and other hypnotic drugs. O'Hanlon, Suppl 1, 38–44

**Insomnia**

Breakthrough in the pharmacologic management of insomnia: overview of the clinical profile of zaleplon. Cluydts, Suppl 1, 45–48  
 Contributions of cognitive-behavioral approaches to the clinical management of insomnia. Morin, Suppl 1, 21–26  
 Current Considerations for the Clinical Management of Insomnia. Suppl 1, 1–48  
 Extent and impact of insomnia as a public health problem. Hublin, Suppl 1, 8–12  
 Guest editor's introduction: diagnosis and treatment of insomnia at the start of the 21st century. Soldatos, Suppl 1, 3–7  
 Insomnia and the 2-process model of sleep regulation: etiopathogenic considerations. Beersma, Suppl 1, 13–16  
 Managing dependence and withdrawal with newer hypnotic medications in the treatment of insomnia. Lader, Suppl 1, 33–37  
 Pharmacotherapy of insomnia: efficacy and rebound with hypnotic drugs. Dikeos, Suppl 1, 27–32  
 Psychological and psychiatric issues in the etiopathogenesis of insomnia. Hauri, Suppl 1, 17–20

**Irritable Bowel Syndrome**

Paroxetine in patients with irritable bowel syndrome: a pilot open-label study. Masand, 12–16

**Mania**

Case report of a manic episode triggered by *S*-adenosylmethionine (SAMe) [letter]. Berigan, 159

**Methylphenidate**

Case report of methylphenidate-induced dyskinesia [letter]. Heinrich, 158–159

**Modafinil**

Modafinil treatment of excessive daytime sedation and fatigue associated with topiramate. Berigan, 249–250

**Mood Disorder Questionnaire**

Mood disorder questionnaire: a simple, patient-rated screening instrument for bipolar disorder. Hirschfeld, 9–11  
 Mood disorder questionnaire in primary care: (not) ready for prime time? [editorial] Manning, 7–8

**Mood Disorders**

Mood disorders in family practice: beyond unipolarity to bipolarity. Manning, 142–152

**Olanzapine**

Comparison of risperidone and olanzapine in bipolar and schizoaffective disorders. Masand, 70–73  
 Olanzapine for the treatment of bipolar disorder [letter]. Ahmed; Masand reply, 113–114

**Pain Management**

Comorbid psychiatric disorders and predictors of pain management program success in patients with chronic pain. Workman, 137–140  
 Panic disorder and chest pain: mechanisms, morbidity, and management. Huffman, 54–62  
 Successful pain management for the recovering addicted patient. Prater, 125–131

**Panic Disorder**

Panic disorder and chest pain: mechanisms, morbidity, and management. Huffman, 54–62

**Paroxetine**

Paroxetine in patients with irritable bowel syndrome: a pilot open-label study. Masand, 12–16

**Patient Care**

Celebrity patients, VIPs, and potentates. Groves, 215–223  
 On the edge of life, I: assessment of, reaction to, and management of the terminally ill recorded in an intensive care unit journal. Sekeres, 178–183  
 On the edge of life, II: house officer struggles recorded in an intensive care unit journal. Sekeres, 184–190  
 When patients are normal people: strategies for managing dual relationships. Jackson, 100–103

**Physician-Patient Relations**

When patients are normal people: strategies for managing dual relationships. Jackson, 100–103

**Primary Care Companion**

New chapter [publisher's note]. 5  
 Physician education [publisher's note]. 124

**PSYCHOTHERAPY CASEBOOK**

Being left. Schuyler, 76–77  
 Cognitive therapy lite. Cluver, 246–248  
 Mastering panic anxiety. Cluver, 155–157  
 Overcoming obstacles: therapeutic success despite external barriers. McLean, 27–29

Psychotherapy of a patient with terminal cancer. Schuyler, 111–112  
 Rethinking the treatment of psychotic disorders. Pelic, 198–199

**Psychotropics**

Safety Profiles of Mood Stabilizers, Antipsychotics, and Broad-Spectrum Psychotropics [EDITOR'S CHOICE]. Suppl 2, 1–65

**Relationship Competence Training**

Developing family relationship competencies [editorial]. Manning, 40  
 Rebuilding family relationship competencies as a primary health intervention. Reiss-Brennan, 41–53

**Reproduction**

Possible link between attention-deficit/hyperactivity disorder and reproductive complications. Lyman, 104–108

**Risperidone**

Comparison of risperidone and olanzapine in bipolar and schizoaffective disorders. Masand, 70–73

**Schizoaffective Disorder**

Comparison of risperidone and olanzapine in bipolar and schizoaffective disorders. Masand, 70–73

**Sedation**

Modafinil treatment of excessive daytime sedation and fatigue associated with topiramate. Berigan, 249–250

**Sexual Dysfunction**

Treating Sexual Dysfunction: Psychiatry's Role in the Age of Sildenafil [EDITOR'S CHOICE]. Suppl 3, 1–25

**Spanish PHQ-9**

Feasibility of using the Spanish PHQ-9 to screen for depression in primary care in Honduras. Wulsin, 191–195

**Stereoisomers**

Escitalopram: a new SSRI for the treatment of depression in primary care. Culpepper, 209–214  
 Stereoisomers in psychiatry: the case of escitalopram. Burke, 20–24

**Suicide, Attempted**

Assessment of patients who attempt suicide. Kishi, 132–136

**Terminal Care see Patient Care****Topiramate**

Modafinil treatment of excessive daytime sedation and fatigue associated with topiramate. Berigan, 249–50

**Withdrawal Symptoms**

Bupropion-associated withdrawal symptoms revisited: a case report [letter]. Berigan, 78

**Women**

Possible link between attention-deficit/hyperactivity disorder and reproductive complications. Lyman, 104–108

**Zaleplon**

Breakthrough in the pharmacologic management of insomnia: overview of the clinical profile of zaleplon. Cluydts, Suppl 1, 45–48  
 Residual effects on memory and psychomotor performance of zaleplon and other hypnotic drugs. O'Hanlon, Suppl 1, 38–44

# THE PRIMARY CARE COMPANION TO THE JOURNAL OF CLINICAL PSYCHIATRY

Author Index to Volume 4: January 2002 Through December 2002

- Ahmed S, Degenhardt EK, McGuire HC.** Olanzapine for the treatment of bipolar disorder [letter with reply]. 113–114
- Ahmed S** see **Manning JS**
- Beersma DGM.** Insomnia and the 2-process model of sleep regulation: etiopathogenic considerations. Suppl 1, 13–16
- Berigan TR.** Bupropion-associated withdrawal symptoms revisited: a case report [letter]. 78
- Berigan TR.** Case report of a manic episode triggered by S-adenosylmethionine (SAMe) [letter]. 159
- Berigan TR.** Many uses of bupropion and bupropion sustained release (SR) in adults [letter]. 30–32
- Berigan TR.** Modafinil treatment of excessive daytime sedation and fatigue associated with topiramate [letter]. 249–250
- Berigan TR.** Uses of newer anticonvulsants: an update [letter]. 200
- Blackwelder RB.** Review of Green MF: *Schizophrenia Revealed: From Neurons to Social Interactions*. 80
- Brescia F** see **Schuyler D**
- Brown ES** see **Morrison KM**
- Bujas-Bobanovic M** see **Kutcher SP**
- Burke WJ, Kratochvil CJ.** Stereoisomers in psychiatry: the case of escitalopram. 20–24
- Buyck D.** Review of Martell CR, Addis ME, Jacobson NS: *Depression in Context: Strategies for Guided Action*. 201
- Christensen DD.** Practical principles for the management of Alzheimer's disease. 63–69
- Cluver JS.** Mastering panic anxiety [PSYCHOTHERAPY CASEBOOK]. 155–157
- Cluver JS, Schuyler D.** Cognitive therapy lite [PSYCHOTHERAPY CASEBOOK]. 246–248
- Cluydts R.** Breakthrough in the pharmacologic management of insomnia: overview of the clinical profile of zaleplon. Suppl 1, 45–48
- Culpepper L.** Escitalopram: a new SSRI for the treatment of depression in primary care. 209–214
- Degenhardt EK** see **Ahmed S**
- Dikeos DG, Soldatos CR.** Pharmacotherapy of insomnia: efficacy and rebound with hypnotic drugs. Suppl 1, 27–32
- Dunderdale BA** see **Groves JE**
- Felker BL** see **Workman EA**
- Frank BL** see **Gupta S**
- Globus JJ.** Review of Kennedy DM: *The ADHD-Autism Connection: A Step Toward More Accurate Diagnosis and Effective Treatments*. 115
- Goli A** see **Morrison KM**
- Greenberg DB.** Clinical dimensions of fatigue. 90–93
- Groves JE, Dunderdale BA, Stern TA.** Celebrity patients, VIPs, and potentates. 215–223
- Gupta S, Lentz B, Frank BL.** Case report of drug-induced dermatitis with weekly fluoxetine [letter]. 78–79
- Gupta S** see **Masand PS**
- Hameed A** see **Masand PS**
- Hauri PJ.** Psychological and psychiatric issues in the etiopathogenesis of insomnia. Suppl 1, 17–20
- Hay DP** see **Manning JS**
- Heck J** see **Wulsin L**
- Heinrich TW.** Case report of methylphenidate-induced dyskinesia [letter]. 158–159
- Hirschfeld RMA.** Mood disorder questionnaire: a simple, patient-rated screening instrument for bipolar disorder. 9–11
- Hubbard JR** see **Workman EA**
- Hublin CGM, Partinen MM.** Extent and impact of insomnia as a public health problem. Suppl 1, 8–12
- Huffman JC, Pollack MH, Stern TA.** Panic disorder and chest pain: mechanisms, morbidity, and management. 54–62
- Jackson WC.** When patients are normal people: strategies for managing dual relationships. 100–103
- Justin RG.** Court appointed volunteers for abused and neglected children. 17–19
- Kaplan DS** see **Masand PS**
- Kathol RG** see **Kishi Y**
- Khan DA** see **Morrison KM**
- King M** see **Masand PS**
- Kirstein JL** see **Reiss-Brennan B**
- Kishi Y, Kathol RG.** Assessment of patients who attempt suicide. 132–136
- Kratochvil CJ** see **Burke WJ**
- Kutcher SP, Lauria-Horner BA, MacLaren CM, Bujas-Bobanovic M.** Evaluating the impact of an educational program on practice patterns in Canadian family physicians interested in depression treatment. 224–231
- Lader MH.** Managing dependence and withdrawal with newer hypnotic medications in the treatment of insomnia. Suppl 1, 33–37
- Lauria-Horner BA** see **Kutcher SP**
- Lentz B** see **Gupta S**
- Lockwood K** see **Masand PS**
- Lyman D.** Possible link between attention-deficit/hyperactivity disorder and reproductive complications. 104–108
- MacLaren CM** see **Kutcher SP**
- Manning JS.** Developing family relationship competencies [editorial]. 40
- Manning JS.** Mood disorder questionnaire in primary care: (not) ready for prime time? [editorial] 7–8
- Manning JS, Ahmed S, McGuire HC, Hay DP.** Mood disorders in family practice: beyond unipolarity to bipolarity. 142–152
- Masand PS.** Reply to Ahmed S: Olanzapine for the treatment of bipolar disorder [letter]. 114
- Masand PS, Gupta S, Schwartz TL, Virk S, Lockwood K, Hameed A, King M, Kaplan DS.** Paroxetine in patients with irritable bowel syndrome: a pilot open-label study. 12–16
- Masand PS, Wang X, Gupta S, Schwartz TL, Virk S, Hameed A.** Comparison of risperidone and olanzapine in bipolar and schizoaffective disorders. 70–73
- McGuire HC** see **Ahmed S; Manning JS**
- McLean LS.** Overcoming obstacles: therapeutic success despite external barriers [PSYCHOTHERAPY CASEBOOK]. 27–29
- Miller KE** see **Prater CD**
- Morin CM.** Contributions of cognitive-behavioral approaches to the clinical management of insomnia. Suppl 1, 21–26
- Morrison KM, Goli A, Wagoner JV, Brown ES, Khan DA.** Depressive symptoms in inner-city children with asthma. 174–177
- O'Hanlon JF.** Residual effects on memory and psychomotor performance of zaleplon and other hypnotic drugs. Suppl 1, 38–44
- Oppenheim D** see **Reiss-Brennan B**
- Parham JS.** Review of Clinton T, Ohlschlager G (eds): *Competent Christian Counseling, Vol. 1: Foundations and Practice of Compassionate Soul Care*. 160
- Partinen MM** see **Hublin CGM**
- Pelic CG, Schuyler D.** Rethinking the treatment of psychotic disorders [PSYCHOTHERAPY CASEBOOK]. 198–199
- Pollack MH** see **Huffman JC**
- Prater CD, Zylstra RG, Miller KE.** Successful pain management for the recovering addicted patient. 125–131
- Quitkin FM.** Depression with atypical features: diagnostic validity, prevalence, and treatment. 94–99

- Reiss-Brennan B, Oppenheim D, Kirstein JL.** Rebuilding family relationship competencies as a primary health intervention. 41–53
- Roberts DE.** Review of Magee M, D'Antonio M: *The Best Medicine: Doctors, Patients, and the Covenant of Caring*. 32
- Schuyler D.** Being left [PSYCHOTHERAPY CASEBOOK]. 76–77
- Schuyler D, Brescia F.** Psychotherapy of a patient with terminal cancer [PSYCHOTHERAPY CASEBOOK]. 111–112
- Schuyler D see Cluver JS; Pelic CG**
- Schwartz TL see Masand PS**
- Sekeres MA, Stern TA.** On the edge of life, I: assessment of, reaction to, and management of the terminally ill recorded in an intensive care unit journal. 178–183
- Sekeres MA, Stern TA.** On the edge of life, II: house officer struggles recorded in an intensive care unit journal. 184–190
- Soldatos CR.** Guest editor's introduction: diagnosis and treatment of insomnia at the start of the 21st century. Suppl 1, 3–7
- Soldatos CR see Dikeos DG**
- Somoza E see Wulsin L**
- Stern TA see Groves JE; Huffman JC; Sekeres MA**
- Virk S see Masand PS**
- Wagoner JV see Morrison KM**
- Wang X see Masand PS**
- Wolff CG.** Cocktails and kitchen sinks [DIARY FROM THE FRONT LINES]. 244–245
- Wolff CG.** Don't cry wolf with me [DIARY FROM THE FRONT LINES]. 153–154
- Wolff CG.** Feeling good and losing weight: the chicken or the egg? [DIARY FROM THE FRONT LINES] 196–197
- Wolff CG.** Hypervigilant? who, me? [DIARY FROM THE FRONT LINES]. 109–110
- Wolff CG.** Post-call blues [DIARY FROM THE FRONT LINES]. 25–26
- Wolff CG.** Yes, we have no bananas [DIARY FROM THE FRONT LINES]. 74–75
- Workman EA, Hubbard JR, Felker BL.** Comorbid psychiatric disorders and predictors of pain management program success in patients with chronic pain. 137–140
- Wulsin L, Somoza E, Heck J.** Feasibility of using the Spanish PHQ-9 to screen for depression in primary care in Honduras. 191–195
- Zylstra RG.** Review of Rudd MD, Joiner T, Rajab MH: *Treating Suicidal Behavior: An Effective, Time-Limited Approach*. 251
- Zylstra RG see Prater CD**